Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Evaluation of a faecal dysbiosis test for irritable bowel syndrome in subjects with and without obesity

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Denosumab vs. zoledronic acid treatment in post-menopausal breast cancer: a 2-year prospective observational study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Quantification of biotin in plasma samples by column switching liquid chromatography - tandem mass spectrometry

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Prognostic utility of serum YKL-40 in patients with cervical cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Estimation of the celiac disease prevalence in Denmark and the diagnostic value of HLA-DQ2/DQ8

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Mortality of older acutely admitted medical patients after early discharge from emergency departments: a nationwide cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Genetic markers of abdominal obesity and weight loss after gastric bypass surgery

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Introducing the "hip call" to facilitate early surgical treatment of hip fractures: A feasibility study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Changes in serum zonulin in individuals with morbid obesity after weight-loss interventions: a prospective cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Biomarkers for irritable bowel syndrome (IBS) are demanded. An altered faecal microbiome has been reported in subjects with IBS and could be a valuable biomarker. This study evaluated the diagnostic properties of a new test for faecal dysbiosis, designed to distinguish IBS from healthy volunteers and compared the prevalence rates of dysbiosis related to IBS and morbid obesity. Subjects with and without morbid obesity and IBS were included. The faecal microbiota was assessed with GA-mapTM Dysbiosis Test (Genetic Analysis AS, Oslo, Norway). The test result was given as dysbiosis (yes/no). Comparisons were made between four groups: subjects with IBS and morbid obesity (IBS+/MO+); subjects without IBS and with morbid obesity (IBS-/MO+); subjects with IBS and without morbid obesity (IBS+/MO-); and healthy volunteers (IBS-/MO-).The prevalence rates of dysbiosis in the groups IBS+/MO+, IBS-/MO+, IBS+/MO- and IBS-/MO- were 18/28 (64%), 45/71 (63%), 31/63 (49%) and 38/91 (42%). Dysbiosis was more prevalent in subjects with morbid obesity, both in those with and without IBS, than in healthy volunteers (p values .04 and .006). Used as a diagnostic test for IBS in subjects without morbid obesity, the positive and negative likelihood ratios (LR) were 1.18 (0.83-1.67) and 0.87 (0.65-1.18), respectively, and in subjects with morbid obesity the LR were 1.01 (95% CI: 0.73-1.41) and 0.98 (0.54-1.75) respectively. The dysbiosis test was unsuitable as a diagnostic test for IBS. Dysbiosis was statistically significantly associated with morbid obesity, but not with IBS.

OriginalsprogEngelsk
TidsskriftScandinavian Journal of Clinical and Laboratory Investigation
Vol/bind78
Udgave nummer1-2
Sider (fra-til)109-113
Antal sider5
ISSN0036-5513
DOI
StatusUdgivet - 2018
Eksternt udgivetJa

ID: 56705258